# AVITA Medical, Inc.: overview RCEL · Nasdaq · CIK 1762303 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/rcel.md) · [Financials](/companies/rcel/financials.md) · [Filings](/companies/rcel/filings.md) · [Insiders](/companies/rcel/insiders.md) Latest reported revenue: [$21.7m](/filings/0001193125-26-338101.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:Revenues, accession 0001193125-26-338101). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [19.5](/filings/0001193125-25-269597.md) | [18.4 d](/filings/0001193125-26-049031.md) | [18.5](/filings/0001193125-26-224107.md) | [18.4](/filings/0001193125-26-338101.md) | [17.1](/filings/0001193125-25-269597.md) | [17.6 d](/filings/0001193125-26-049031.md) | [19.3](/filings/0001193125-26-224107.md) | [21.7](/filings/0001193125-26-338101.md) | | Gross margin | % | [83.7%](/filings/0001193125-25-269597.md) | [87.6% d](/filings/0001193125-26-049031.md) | [84.7%](/filings/0001193125-26-224107.md) | [81.2%](/filings/0001193125-26-338101.md) | [81.3%](/filings/0001193125-25-269597.md) | [81.2% d](/filings/0001193125-26-049031.md) | [81.7%](/filings/0001193125-26-224107.md) | [81.9%](/filings/0001193125-26-338101.md) | | Operating margin | % | [(70.6%)](/filings/0001193125-25-269597.md) | [(54.1%) d](/filings/0001193125-26-049031.md) | [(63.9%)](/filings/0001193125-26-224107.md) | [(60.5%)](/filings/0001193125-26-338101.md) | [(53.6%)](/filings/0001193125-25-269597.md) | [(59.1%) d](/filings/0001193125-26-049031.md) | [(45.7%)](/filings/0001193125-26-224107.md) | [(31.6%)](/filings/0001193125-26-338101.md) | | Net margin | % | [(82.9%)](/filings/0001193125-25-269597.md) | [(63.0%) d](/filings/0001193125-26-049031.md) | [(74.9%)](/filings/0001193125-26-224107.md) | [(53.9%)](/filings/0001193125-26-338101.md) | [(77.3%)](/filings/0001193125-25-269597.md) | [(66.0%) d](/filings/0001193125-26-049031.md) | [(55.1%)](/filings/0001193125-26-224107.md) | [(35.3%)](/filings/0001193125-26-338101.md) | | Diluted EPS | $ per share | [(0.62)](/filings/0001193125-25-269597.md) | not reported | [(0.53)](/filings/0001193125-26-224107.md) | [(0.38)](/filings/0001193125-26-338101.md) | [(0.46)](/filings/0001193125-25-269597.md) | not reported | [(0.35)](/filings/0001193125-26-224107.md) | [(0.25)](/filings/0001193125-26-338101.md) | | Free cash flow | $m | [(11.0) d](/filings/0001193125-25-269597.md) | [(9.7) d](/filings/0001193125-26-338101.md) | [(10.5)](/filings/0001193125-26-224107.md) | [(10.8) d](/filings/0001193125-26-338101.md) | [(6.2) d](/filings/0001193125-25-269597.md) | [(6.1) d](/filings/0001193125-26-338101.md) | [(10.1)](/filings/0001193125-26-224107.md) | [(3.6) d](/filings/0001193125-26-338101.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-06-30) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [29.2](/filings/0001564590-23-002302.md) | [34.4](/filings/0000950170-24-018748.md) | [50.1](/filings/0000950170-25-020026.md) | [64.3](/filings/0001193125-26-049031.md) | [71.6](/filings/0001193125-26-049031.md) | | Gross margin | % | [79.6%](/filings/0001564590-23-002302.md) | [82.4%](/filings/0000950170-24-018748.md) | [84.5%](/filings/0000950170-25-020026.md) | [85.8%](/filings/0001193125-26-049031.md) | [82.1%](/filings/0001193125-26-049031.md) | | Operating margin | % | [(90.8%)](/filings/0001564590-23-002302.md) | [(79.9%)](/filings/0000950170-24-018748.md) | [(85.1%)](/filings/0000950170-25-020026.md) | [(88.1%)](/filings/0001193125-26-049031.md) | [(59.4%)](/filings/0001193125-26-049031.md) | | Net margin | % | [(90.9%)](/filings/0001564590-23-002302.md) | [(77.5%)](/filings/0000950170-24-018748.md) | [(70.6%)](/filings/0000950170-25-020026.md) | [(96.3%)](/filings/0001193125-26-049031.md) | [(67.8%)](/filings/0001193125-26-049031.md) | | Diluted EPS | $ per share | [1.17](/filings/0001564590-23-002302.md) | [1.07](/filings/0000950170-24-018748.md) | [(1.40)](/filings/0000950170-25-020026.md) | [(2.39)](/filings/0001193125-26-049031.md) | [(1.74)](/filings/0001193125-26-049031.md) | | Free cash flow | $m | [(26.8)](/filings/0001564590-23-002302.md) | [(19.5)](/filings/0000950170-24-018748.md) | [(39.4)](/filings/0000950170-25-020026.md) | [(58.1)](/filings/0001193125-26-338101.md) | [(32.2)](/filings/0001193125-26-338101.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/rcel/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $5.5m | 1,333,914 | | Reduced −1,238 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $2.3m | 564,952 | | Reduced −568,174 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $1.4m | 339,822 | | Reduced −203,152 | | [MARSHALL WACE, LLP](/funds/1318757.md) | 2026-06-30 | $1.4m | 338,387 | | Added +285,825 | | [AQR CAPITAL MANAGEMENT LLC](/funds/1167557.md) | 2026-06-30 | $1.3m | 321,013 | | Added +226,652 | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $827.9k | 200,462 | | Added +42,841 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $753.3k | 182,402 | | Reduced −11,034 | | [NewEdge Advisors, LLC](/funds/1633516.md) | 2026-06-30 | $615.1k | 148,931 | | New +148,931 | | [MACQUARIE GROUP LTD](/funds/1418333.md) | 2026-06-30 | $595.4k | 144,164 | | Added +132,262 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $532.7k | 128,977 | | Reduced −300,045 | ## Recent filings [All 374 filings](/companies/rcel/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-11 | 16:30 ET | [8-K](/filings/0001193125-26-344787.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001193125-26-344787 | | 2026-08-06 | 16:25 ET | [8-K/A](/filings/0001193125-26-338135.md) | 5.07 Shareholder vote results | 0001193125-26-338135 | | 2026-08-06 | 16:20 ET | [10-Q](/filings/0001193125-26-338101.md) | Quarterly report, period 2026-06-30 | 0001193125-26-338101 | | 2026-08-06 | 16:10 ET | [8-K](/filings/0001193125-26-338011.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-338011 | | 2026-06-08 | 19:25 ET | [8-K](/filings/0001762303-26-000011.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001762303-26-000011 | | 2026-06-04 | 19:19 ET | [8-K](/filings/0001762303-26-000003.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results | 0001762303-26-000003 | | 2026-05-14 | 16:20 ET | [10-Q](/filings/0001193125-26-224107.md) | Quarterly report, period 2026-03-31 | 0001193125-26-224107 | | 2026-05-14 | 16:10 ET | [8-K](/filings/0001193125-26-224022.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-224022 | | 2026-05-01 | 16:54 ET | [8-K](/filings/0001193125-26-201662.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-201662 | | 2026-04-22 | 16:30 ET | [DEF 14A](/filings/0001193125-26-170562.md) | Proxy statement, period 2026-04-22 | 0001193125-26-170562 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-049031.md), filed Feb 12, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/d5a970e3-025b-4807-b045-9e9a311b6b77) ## About the filer - CIK: 1762303 - Tickers: RCEL, AVHHL - Exchange: Nasdaq - SIC code: 3841 Surgical & Medical Instruments & Apparatus - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.